Endothelin (ET) receptors are widely expressed within the human body with one of their major functions being regulation of the vascular tone. Pulmonary arterial hypertension and other complications associated with SSc are related to the function and or dysregulation of these receptors. As ET receptors also play a crucial role in SSc, this review will discuss the expression and physiological functions of ET receptors in the human organism, their signalling pathways, the complications of diseases they are associated with and their importance as a therapeutic target in SSc.
The ET receptors were discovered by pharmacological in vitro and in vivo studies showing different effects for the three isoforms of ET. To date, there are at least two known human ET receptors: the ET A receptor and the ET B receptor. ET B is usually classified into two subtypes, termed ET B1 and ET B2 , which most likely result from alternative splicing, but the evidence is considered controversial, as is the case for the subtypes ET A1 and ET A2 .
Although ET receptors are expressed almost ubiquitously in humans, distribution and expression of the ET receptors depend on the respective organ, the tissue type and the developmental stage but may also be influenced by a given disease. ET A is primarily expressed in vascular smooth muscle cells and stromal tissues, whereas ET B is mainly expressed in vascular endothelial and epithelial tissues as well as by smooth muscle cells. However, ET receptors are also found in nonvascular structures.
The three isoforms of ET (ET-1, ET-2 and ET-3) bind with different affinities to the two ET receptors. Both ET receptors can bind all endothelin isoforms, but ET A shows a much higher affinity for ET-1, the most abundant ET in human plasma, than for ET-3, which is found at high levels in human brain. ET B , on the other hand, binds all three ET isoforms with equal affinity.
The major function of ET A along with its ligand ET-1 consists in maintaining a normal vascular tone by modulating vasoconstriction and retention of sodium. Activation of ET A increases blood pressure. ET B is a more complex molecule because it can exert opposing effects depending on its location: ET B activation of smooth muscle cells results in vasoconstriction, whereas ET B activation on vascular endothelium causes vasodilatation through the release of nitric oxide by inducing NOS-III. ET B also lowers blood pressure through increased natriuresis and diuresis. ET B can induce the release of prostaglandins. In non-vascular tissues such as kidney, ET B may serve to clear ETs from circulation by receptor-mediated uptake and subsequent lysosomal degradation.
ET receptors can mediate stimulation of proliferation of different cell types. For example, smooth muscle cell proliferation is mainly stimulated via the ET A receptor, while proliferation of astrocytes is stimulated via the ET B receptor. In most cells, ETs exert co-stimulatory effects via their receptors, increasing the effects of other growth factors. The importance of ET receptors in proliferation and development has been underlined by gene disruption and mutational studies in animal models for embryonic development [1] . ET receptors are also involved in modulating inflammation. Macrophages express ET B [2] and upon activation by ET-1 release cytokines, chemokines and free radicals. Other functions include activation of neutrophils and mast cells.
There are many mediators that are able to regulate the expression of ET receptors. Epidermal growth factor, basic fibroblast growth factor, cAMP and hypoxia result in up-regulation of the ET A receptor, while platelet-derived growth factor, angiotensin II, TGF-and the endothelins themselves down-regulate ET A expression. ET B is regulated in an opposing fashion: its production is up-regulated by angiotensin II and down-regulated by cAMP and catecholamines. The ET B receptor is a regulator itself: ET-1 synthesis is regulated by ET B , thus creating an autoregulatory mechanism.
Signalling of ET receptors
ET receptors belong to the group of G-protein-coupled receptors. The dissociated G-protein subunit activates phospholipase C (PLC), which cleaves phosphatidylinositol-4,5-bisphosphate (PIP 2 ) to form inositol-1,4,5-trisphosphate (IP 3 ) and diacylglycerol (DAG). IP 3 stimulates the release of Ca 2þ from intracellular calcium stores. In a second phase, this opens calcium channels within the plasma membrane, which further increases the intracellular Ca 2þ concentration by influx of calcium ions. In some smooth muscle cells, this also leads to the opening of Ca 2þ -activated potassium channels. DAG along with the elevated Ca 2þ concentrations activates protein kinase C (PKC). The activation of PKC is probably responsible for some of the nonvascular effects of endothelins, such as stimulation of proliferation. Further signalling pathways induced by the ET receptors include phospholipase D (PLD)-, mitogen-activated protein kinase (MAPK)-and p125 focal adhesion kinase (FAK)-dependent pathways. However, much less is known about how the ET receptors actually modulate these pathways. Depending on the distribution and type of ion channels and the signalling network of cells, ET B in particular can mediate different effects in different tissues and organs.
However, it should be mentioned that there may be some 'cross-talk' between the two ET receptors: although ET A and ET B have different affinities for the ET isoforms and can elicit different cellular responses, there is some evidence that ET B may require ET A for fully recognizing and binding ET-1 by forming an ET A -ET B receptor heterodimer [3] .
Clinical relevance
Endothelin receptors play an important role in various diseases. Receptors and disease are most often associated with over-or underexpression of the receptors. Expression of ET-1 and ET B is increased in certain renal diseases [4] . In scleroderma-associated pulmonary fibrosis, ET A levels were significantly decreased, while ET B levels were slightly increased [5] . Diabetes animal models show overexpression of ET A and ET B in the renal cortex [6] . Most abnormalities concerning the ET receptors are associated with vascular diseases. Ischaemic heart diseases, for example, induce up-regulation of ET A and ET B in human coronary arteries [7] . ET receptors are also involved in inflammatory processes. For example, experimentally induced airway inflammation caused an increase of ET B in bronchial smooth muscle cells [8] and diabetic renal injury could be reduced via an anti-inflammatory mechanism [9] .
ET receptors as therapeutic target in SSc
As mentioned previously, ET receptors have several primary sites of expression. Nonetheless, they are widely expressed in many tissues and organs including lung, kidney, liver and skin, which suggests numerous biological effects for the ET receptors in vivo. Vice versa, dysregulation of the ET system can affect many tissues and organs as is the case in SSc. The pathogenesis of SSc is complex but excessive fibrosis and vascular disorders are typical features. These often result in interstitial fibrosis of the pulmonary system and pulmonary vascular disease leading to pulmonary arterial hypertension (PAH) still being a dominant cause of death in SSc. Based on the pathophysiological mechanisms as outlined earlier, ET receptors are an attractive target to improve these sequelae. Several antagonists have been developed for blocking the ET receptors, yet only few are able fulfil the pharmacological and toxicological criteria for successful clinical studies. Amongst these are bosentan, an inhibitor of both ET A and ET B , and sitaxentan and ambrisentan, which are highly selective for ET A .
Many studies are addressing the question whether dual inhibitors or selective ET A inhibitors are the best option for treating SSc and its complications. Selective ET A inhibitors would in theory have the advantage not to reduce the vasodilative effects of ET B and the clearance of ET-1 from circulation by ET B . On the other hand, treatment with dual inhibitors is theoretically favoured by the following evidence: (i) both ET A and ET B are involved in increased collagen synthesis and secretion via ET-1 [10] . (ii) In SSc, the elevated vascular tone is not only due to vasoconstriction but also due to increased proliferation of cells in the vascular walls, a process in which ET B is involved. Therefore, clinical studies will have to show whether selective or non-selective inhibition provides the best treatment with the least side-effects.
Endothelin receptors are widely expressed in the human organism, but distribution and expression depend on the organ, the tissue type, the developmental stage and may be modulated by the underlying disease. The ET A receptor and the ET B receptor have different primary locations of expression and partially opposing functions (depending on the location). The endothelin receptors are G-protein-coupled receptors capable of inducing a number of signalling pathways including PLC-, PLD-, PKC-, MAPK-and FAK-dependent pathways. Besides regulating the vascular tone, the endothelin receptors are also involved in processes of proliferation, inflammation and development. Endothelin receptors represent a promising therapeutic target for SSc-associated complications such as PAH.
